Gain Therapeutics (NASDAQ:GANX) Given Buy Rating at Chardan Capital

Chardan Capital restated their buy rating on shares of Gain Therapeutics (NASDAQ:GANX) in a report issued on Wednesday morning, Benzinga reports. They currently have a $6.00 price target on the stock.

Separately, HC Wainwright dropped their price target on Gain Therapeutics from $10.00 to $9.00 and set a buy rating on the stock in a research note on Monday, December 4th.

Gain Therapeutics Stock Performance

Shares of GANX stock opened at $3.73 on Wednesday. The business’s 50 day simple moving average is $4.29 and its 200 day simple moving average is $3.44. Gain Therapeutics has a one year low of $2.00 and a one year high of $6.19. The stock has a market capitalization of $48.15 million, a PE ratio of -2.06 and a beta of 0.47. The company has a debt-to-equity ratio of 0.06, a current ratio of 2.30 and a quick ratio of 2.30.

Institutional Investors Weigh In On Gain Therapeutics

Institutional investors have recently bought and sold shares of the stock. Royal Bank of Canada grew its stake in Gain Therapeutics by 947.6% in the 3rd quarter. Royal Bank of Canada now owns 210,000 shares of the company’s stock valued at $689,000 after purchasing an additional 189,954 shares during the period. Geode Capital Management LLC grew its stake in Gain Therapeutics by 47.3% in the 2nd quarter. Geode Capital Management LLC now owns 138,721 shares of the company’s stock valued at $621,000 after purchasing an additional 44,514 shares during the period. Renaissance Technologies LLC bought a new position in Gain Therapeutics in the 2nd quarter valued at $119,000. Northern Trust Corp grew its stake in Gain Therapeutics by 227.7% in the 4th quarter. Northern Trust Corp now owns 43,513 shares of the company’s stock valued at $142,000 after purchasing an additional 30,236 shares during the period. Finally, Vanguard Group Inc. grew its stake in Gain Therapeutics by 25.8% in the 4th quarter. Vanguard Group Inc. now owns 88,385 shares of the company’s stock valued at $289,000 after purchasing an additional 18,105 shares during the period. Institutional investors own 11.97% of the company’s stock.

About Gain Therapeutics

Gain Therapeutics, Inc, a biotechnology company, researches and develops novel therapies to treat diseases caused by protein misfolding in Switzerland and Spain. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease.